Literature DB >> 20438745

Ex vivo delta opioid receptor autoradiography: CNS receptor occupancy of two novel compounds over their antihyperalgesic dose range.

Ellen E Codd1, Jianya Ma, Sui-Po Zhang, Dennis J Stone, Raymond W Colburn, Michael R Brandt, Kristen M Chevalier, Yongxin Zhu, Sean Peng, Chaozhong Cai, Paul D Acton, Christopher M Flores.   

Abstract

Discovered as part of an effort to identify delta opioid (DOPr or DOR) agonist analgesics, JNJ-20788560 and JNJ-39204880 exhibited high DOR affinity, with K(i) values of 1.7 and 2.0nM, respectively, and were selective for DOR over the mu opioid receptor (MOPr or MOR), with 596- and 122-fold selectivity, respectively. Both compounds stimulated DOR but not MOR induced GTPgammaS binding and were effective antihyperalgesic agents in the complete Freund's adjuvant model of thermal hyperalgesia in the rat, with oral ED(50) values of 13.5 and 35mg/kg, corresponding to plasma levels of 1 and 9microM, respectively. Autoradiographic analysis of DOR and MOR occupancy in sections of brain (striatum) and lumbar spinal cord (L4-L6) was determined ex vivo, using radiolabeled naltrindole or DAMGO. Quantitative image analysis resulted in striatal DOR ED(50) values of 6.9 and 10.7mg/kg, for JNJ-20788560 and JNJ-39204880 respectively, and spinal cord values of 6.4 and 3.2mg/kg, respectively. Neither compound dose-dependently occupied MOR within the dose range studied. Thus, this study confirmed the DOR selectively over MOR of both compounds following their oral administration, and further demonstrated dose-dependent DOR occupancy by each compound across its antihyperalgesic dose range. Importantly, these in vitro, in vivo, and ex vivo data revealed that the greater in vitro potency of JNJ-20788560 was paralleled by its greater in vivo potency, although JNJ-39204880 achieved higher plasma levels following its oral administration. The receptor occupancy levels observed at the pharmacologic ED(50) doses of these compounds suggest the need for greater target engagement by JNJ-39204880 than by JNJ-20788560 to elicit a similar therapeutic response. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20438745     DOI: 10.1016/j.pbb.2010.04.020

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  3 in total

Review 1.  Delta opioid receptor analgesia: recent contributions from pharmacology and molecular approaches.

Authors:  Claire Gavériaux-Ruff; Brigitte Lina Kieffer
Journal:  Behav Pharmacol       Date:  2011-09       Impact factor: 2.293

Review 2.  Delta Opioid Pharmacology in Relation to Alcohol Behaviors.

Authors:  Doungkamol Alongkronrusmee; Terrance Chiang; Richard M van Rijn
Journal:  Handb Exp Pharmacol       Date:  2018

3.  The novel mu-opioid antagonist, GSK1521498, reduces ethanol consumption in C57BL/6J mice.

Authors:  Tamzin L Ripley; Sandra Sanchez-Roige; Edward T Bullmore; Manolo Mugnaini; Kay Maltby; Sam R Miller; David R Wille; Pradeep Nathan; David N Stephens
Journal:  Psychopharmacology (Berl)       Date:  2015-07-05       Impact factor: 4.530

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.